2024-513601-31-00招募中2 期
Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z (ARI-0001 cells) in patients with CD19+ acute lymphoid leukemia resistant or refractory to therapy
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer9 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2024年5月13日最近更新:
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 32
- 试验地点
- 9
- 主要终点
- Response rate with measurable residual disease negative by multiparametric flow cytometry 28 days after infusion of ARI-0001 cells.
研究概览
简要总结
To assess the efficacy (in terms of response rate and duration) of the infusion of ARI-0001 cells (Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity [A3B1] conjugated to the 4-aBB and CD3z co-stimulatory regions) in patients with resistant or refractory CD19+ acute lymphoid leukemia
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Diagnoses of CD19+ acute lymphoid leukemia, with a life expectancy of less than 2 years that meet the following conditions: Relapsed/refractory not candidate for transplantation (due to associated diseases or absence of donor) or in allogenic post-transplant relapse.
- •Measurable disease understood as the presence of measurable residual disease by flow cytometry in bone marrow or peripheral blood
- •Age less than 70 years (from 18 to 70)
- •ECOG functional status from 0 to 2
- •Life expectancy of at least 3 months.
- •Adequate venous access to perform a lymphapheresis. Absence of contraindications for it
- •Signature of informed consent
排除标准
- •Treatment with any experimental or non-marketed substance within four weeks prior to recruitment, or actively participating in another therapeutic trial
- •Positive serology for hepatitis B, defined as a positive test for HBsAg. In addition, if the patient is HBsAg negative but has anti-HBc antibodies it will be necessary to perform a DNA test of the hepatitis B virus, and if the result is positive the patient will be excluded
- •Positive serology for hepatitis C, defined as a positive test for anti-VHC antibodies confirmed by RIBA
- •Concurrent uncontrolled medical illnesses including cardiac, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological or psychiatric diseases that in the opinion of the investigator are potential risk factors to the patient
- •Severe organ involvement, defined as cardiac ejection fraction <40%; DLCO <40%; calculated glomerular filtrate <30 ml/min; or bilirubin > 3 times the upper limit of normality (unless Gilbert syndrome)
- •Pregnant or lactating women. Woman of childbearing potential should have a negative pregnancy test in the screening phase.
- •Women of childbearing potential, including those whose last menstrual cycle was in the year prior to screening, who are unable or unwilling to use highly effective contraceptive methods* from the start of the study to the completion of the study.
- •Men who cannot or do not wish to use highly effective contraceptive methods* from the beginning of the study until the end of the study
- •Previous treatment with CART therapy (commercial or experimental)
- •Diagnosis of another neoplasm, past or present. Patients may be included in complete remission for more than 3 years, or have a history of non-melanoma skin cancer or in-situ carcinoma resected completely.
- •Relief of central nervous system (CNS-3) at the time of inclusion. Inclusion will be permitted in patients with a lower grade (CNS-2) or CNS-3 who have responded to intrathecal chemotherapy
- •Isolated extramedullary involvement (i.e. in the absence of minimal residual disease in peripheral blood, bone marrow, or cerebrospinal fluid)
- •Early relapse after transplantation (less than 3 months for mononuclear cell apheresis, less than 6 months for infusion of ARI-0001)
- •Active immunosuppressive treatment for graft-versus-host disease and other diseases. The use of corticosteroids to control leukaemia at the time of inclusion should be limited as much as possible and should be discontinued prior to infusion of ARI-0001 cells.
- •Active infection requiring systemic medical treatment such as chronic kidney infection, chronic lung infection or tuberculosis.
- •HIV infection
结局指标
主要结局
Response rate with measurable residual disease negative by multiparametric flow cytometry 28 days after infusion of ARI-0001 cells.
Response rate with measurable residual disease negative by multiparametric flow cytometry 28 days after infusion of ARI-0001 cells.
次要结局
- Duration of response
- Best response during the first 3 months of follow-up after administration of the first fractioned dose of ARI-0001
- Progression-free survival at 6 months and 1 year of the infusion and after the signature of informed consent.
- Overall Survival (OS) at 1 year of the infusion and after the informed consent form signature
- Assessment of ARI-0001 cell toxicity considering special interest in the following adverse events: CRS (cytokine release syndrome), encephalopathy associated with CARs (ICANS) and cerebral edema. Mortality related to study procedures and adverse events grade 3-4 will be evaluated at month 3 and year 1. Intensity will be assessed using CTCAE version 5.0 scale. To evaluate CRS and neurotoxicity ASTCT criteria will be used.
- In vivo survival of ARI-0001 cells in peripheral blood, bone narrow and cerebrospinal fluid, to be determined by flow cytometry and quantitative transgene PCR with monthly frequency in the first 6 months and thereafter quarterly up to 2 years of infusion
研究者
Jordi Esteve Reyner
Scientific
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
研究点 (9)
Loading locations...
相似试验
已完成
1 期
Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)InfluenzaNCT00349141Alachua Government Services, Inc.270
已完成
1 期
Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.Chronic Graft-Versus-Host DiseaseNCT01956903Grupo Espanol de trasplantes hematopoyeticos y terapia celular15
已完成
1 期
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck CancersUrothelial CarcinomaHead and Neck CancerBladder Urothelial CarcinomaMelanomaNCT02989064Adaptimmune10
进行中（未招募）
1 期
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast CancerBreast CancerNCT01872260Novartis Pharmaceuticals259
已完成
2 期
Phase II Artesunate Study in Severe MalariaMalariaNCT00522132Medicines for Malaria Venture200